View ValuationNeurAxis 향후 성장Future 기준 점검 5/6NeurAxis은 연간 수입과 매출이 각각 85.8%와 61.2% 증가할 것으로 예상되고 EPS는 연간 88.1%만큼 증가할 것으로 예상됩니다.핵심 정보85.8%이익 성장률88.06%EPS 성장률Medical Equipment 이익 성장16.2%매출 성장률61.2%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트29 May 2026최근 향후 성장 업데이트Major Estimate Revision • May 19Consensus EPS estimates fall by 60%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$0.55 to -US$0.88 per share. Revenue forecast of US$10.2m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$11.00 unchanged from last update. Share price fell 9.1% to US$7.41 over the past week.Major Estimate Revision • Mar 26Consensus revenue estimates increase by 12%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$8.50m to US$9.55m. EPS estimate unchanged at -US$0.54. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target up from US$7.00 to US$11.00. Share price fell 3.2% to US$6.93 over the past week.Breakeven Date Change • Mar 19Forecast to breakeven in 2028The analyst covering NeurAxis expects the company to break even for the first time. New forecast suggests losses will reduce by 7.5% per year to 2027. The company is expected to make a profit of US$5.10m in 2028. Average annual earnings growth of 96% is required to achieve expected profit on schedule.Price Target Changed • Nov 14Price target decreased by 20% to US$5.00Down from US$6.25, the current price target is an average from 2 analysts. New target price is 113% above last closing price of US$2.35. Stock is down 28% over the past year. The company is forecast to post a net loss per share of US$0.91 next year compared to a net loss per share of US$1.22 last year.공시 • May 24Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025NeurAxis, Inc. provided earnings guidance for late 2024 and 2025 . Given the company's recent success with new payor coverage, the company expects revenue to increase in late 2024 and into 2025.공시 • Apr 10NeurAxis, Inc. Provides Revenue Guidance in Late 2024 and into 2025NeurAxis, Inc. provided revenue guidance for late 2024 and 2025. Given the company's recent success with new payor coverage, the company expects the company's revenue to increase in late 2024 and into 2025.모든 업데이트 보기Recent updatesMajor Estimate Revision • May 19Consensus EPS estimates fall by 60%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$0.55 to -US$0.88 per share. Revenue forecast of US$10.2m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$11.00 unchanged from last update. Share price fell 9.1% to US$7.41 over the past week.Reported Earnings • May 13First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$0.18 loss per share (improved from US$0.33 loss in 1Q 2025). Revenue: US$1.61m (up 80% from 1Q 2025). Net loss: US$1.95m (loss narrowed 22% from 1Q 2025). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 5.3%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.공시 • May 05NeurAxis, Inc. to Report Q1, 2026 Results on May 12, 2026NeurAxis, Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026공시 • Apr 29NeurAxis, Inc., Annual General Meeting, Jun 10, 2026NeurAxis, Inc., Annual General Meeting, Jun 10, 2026. Location: 11611 n., meridian st, suite 330, carmel, in 46032, United StatesMajor Estimate Revision • Mar 26Consensus revenue estimates increase by 12%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$8.50m to US$9.55m. EPS estimate unchanged at -US$0.54. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target up from US$7.00 to US$11.00. Share price fell 3.2% to US$6.93 over the past week.Breakeven Date Change • Mar 19Forecast to breakeven in 2028The analyst covering NeurAxis expects the company to break even for the first time. New forecast suggests losses will reduce by 7.5% per year to 2027. The company is expected to make a profit of US$5.10m in 2028. Average annual earnings growth of 96% is required to achieve expected profit on schedule.공시 • Mar 12NeurAxis, Inc. to Report Q4, 2025 Results on Mar 19, 2026NeurAxis, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 19, 2026공시 • Jan 08NeurAxis, Inc. Achieves Major Milestone with AMA Category I CPT®? Code Now in Effect, Establishing A Permanent Reimbursement PathwayNeurAxis, Inc. announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now in effect, completing a successful commercial milestone for the Company. The assignment of the Category I CPT code is one of the most significant breakthroughs in efforts towards widespread adoption of IB-Stim®?. This establishes a permanent, nationally recognized coding and billing pathway for NeurAxis' PENFS therapy, reflecting broad clinical acceptance and meeting the American Medical Association's (AMA) criteria for widespread utilization, clinical efficacy, and established standards of care. Category I CPT codes are routinely used by Medicare, Medicaid, and commercial insurers as a basis for coverage and payment determinations. NeurAxis believes the code's implementation will expand patient access, reinforce the durability of its reimbursement model, and enhance the predictability of its commercial trajectory.New Risk • Nov 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.3m free cash flow). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$3.5m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$3.4m revenue). Market cap is less than US$100m (US$24.9m market cap).Price Target Changed • Nov 14Price target decreased by 20% to US$5.00Down from US$6.25, the current price target is an average from 2 analysts. New target price is 113% above last closing price of US$2.35. Stock is down 28% over the past year. The company is forecast to post a net loss per share of US$0.91 next year compared to a net loss per share of US$1.22 last year.공시 • Nov 13NeurAxis, Inc. Announces New Medical Policy Coverage for Percutaneous Electrical Nerve Field Stimulation, Representing Approximately 566,000 Total Covered Lives, in MichiganNeurAxis, Inc. announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric beneficiaries in Michigan now have access to PENFS under medical policy. This expansion increases NeurAxis' total national coverage to roughly 55 million total lives, with additional payer decisions from major insurers expected in the coming months. NeurAxis' proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (nausea symptoms) in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in theear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns--underscoring IB-Stim's unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.Reported Earnings • Nov 12Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.23 loss per share. Revenue: US$811.4k (up 22% from 3Q 2024). Net loss: US$2.32m (loss widened 29% from 3Q 2024). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 72% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.공시 • Nov 04NeurAxis, Inc. to Report Q3, 2025 Results on Nov 11, 2025NeurAxis, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 11, 2025공시 • Oct 24NeurAxis Receives First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia with Associated Nausea Symptoms in the Adult Patient PopulationNeurAxis, Inc. announced that it has received FDA 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (PENFS) technology for the treatment of functional abdominal pain (FAP) associated with functional dyspepsia (FD), and FD related nausea symptoms, in patients aged 8 years and older. The FDA reviewed the clinical literature supporting the use of NeurAxis' PENFS technology, including randomized controlled trials and real-world evidence demonstrating the device's safety and effectiveness in pediatric patients and individuals up to 21 years of age. Based on this comprehensive review, the FDA extrapolated the data to adults, supporting the use of PENFS in patients aged 8 years and years. This expanded indication marks a historic milestone, the first FDA clearance or approval for a treatment specifically addressing functional dyspepsia in adults. NeurAxis' PenFS technology is a non-surgical device that sends gentle electrical impulses into cranial nerve batteries in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction (DGBIs) and no approved drug therapies for adults for pain with functional dyspepsia. Pharmacologic treatments that use drugs off-label can often have serious side effects, and most lack scientific evidence of efficacy.공시 • Aug 30NeurAxis, Inc. has filed a Follow-on Equity Offering in the amount of $3.3 million.NeurAxis, Inc. has filed a Follow-on Equity Offering in the amount of $3.3 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Aug 13Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: US$0.22 loss per share (improved from US$0.42 loss in 2Q 2024). Revenue: US$894.1k (up 46% from 2Q 2024). Net loss: US$1.90m (loss narrowed 35% from 2Q 2024). Revenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.공시 • Aug 05NeurAxis, Inc. to Report Q2, 2025 Results on Aug 12, 2025NeurAxis, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 12, 2025공시 • Jun 10Neuraxis, Inc. Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (Fap) in IbsNeurAxis, Inc. announced that its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been officially incorporated into newly released clinical practice guidelines issued by the leading pediatric academic society for the treatment of Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS). This inclusion represents a major catalyst for NeurAxis, unlocking the potential for large-scale insurance coverage for its product, IB-Stim, and setting the stage for accelerated growth through evidence-based recommendations. This rigorous, evidence-based approach that incorporates PENFS as an important treatment option for children elevates NeurAxis's profile within the healthcare industry and supports wider market adoption of IB-Stim. Abdominal pain in IBS affects millions globally, creating a multi-billion-dollar market opportunity with limited effective treatment options. IB-Stim is the only pediatric treatment option that the FDA has cleared for FAP in IBS and abdominal pain in functional dyspepsia (to include nausea symptoms) for patients 8-21 years old. IB-Stim delivers gentle electrical impulses to cranial nerve bundles in the ear, offering a safe, non-invasive alternative to drug therapies often used off-label and many of which are not suggested in the practice guidelines from NASPGHAN /ESPGHAN.New Risk • May 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (US$26.5m market cap).공시 • May 23NeurAxis, Inc. has completed a Follow-on Equity Offering in the amount of $4.999998 million.NeurAxis, Inc. has completed a Follow-on Equity Offering in the amount of $4.999998 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,538,461 Price\Range: $3.25 Discount Per Security: $0.2275 Transaction Features: Registered Direct Offering공시 • May 21NeurAxis, Inc. has filed a Follow-on Equity Offering in the amount of $4.999998 million.NeurAxis, Inc. has filed a Follow-on Equity Offering in the amount of $4.999998 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,538,461 Price\Range: $3.25 Discount Per Security: $0.2275 Transaction Features: Registered Direct OfferingReported Earnings • May 13First quarter 2025 earnings released: US$0.33 loss per share (vs US$0.32 loss in 1Q 2024)First quarter 2025 results: US$0.33 loss per share (further deteriorated from US$0.32 loss in 1Q 2024). Revenue: US$895.7k (up 39% from 1Q 2024). Net loss: US$2.49m (loss widened 18% from 1Q 2024). Revenue is forecast to grow 59% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.공시 • May 05NeurAxis, Inc. to Report Q1, 2025 Results on May 12, 2025NeurAxis, Inc. announced that they will report Q1, 2025 results Pre-Market on May 12, 2025New Risk • Apr 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.1m free cash flow). Earnings have declined by 28% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$2.7m revenue). Market cap is less than US$100m (US$14.1m market cap).공시 • Apr 07NeurAxis, Inc., Annual General Meeting, May 29, 2025NeurAxis, Inc., Annual General Meeting, May 29, 2025. Location: at 11611 n., meridian st, suite 330, in 46032., carmel United StatesReported Earnings • Mar 21Full year 2024 earnings released: US$1.22 loss per share (vs US$4.50 loss in FY 2023)Full year 2024 results: US$1.22 loss per share (improved from US$4.50 loss in FY 2023). Revenue: US$2.69m (up 9.2% from FY 2023). Net loss: US$8.45m (loss narrowed 42% from FY 2023).공시 • Mar 12NeurAxis, Inc. to Report Q4, 2024 Results on Mar 20, 2025NeurAxis, Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 20, 2025공시 • Jan 22NeurAxis, Inc. Announces New Medical Policy Coverage with a Prominent Insurer for over Five Million Lives Across Multiple StatesNeurAxis, Inc. announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with a prominent insurer, with approximately 5.1 million members across 13 states. NeurAxis' PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction. Off label pharmacologic treatments can often have serious side effects, and most lack scientific evidence of efficacy.공시 • Dec 11NeurAxis Inc. Announces FDA 510(k) Clearance of Red for Testing and Evaluation of Patients with Chronic ConstipationNeurAxis, Inc. announced the US Food and Drug Administration (FDA) granted a 510(k) clearance for RED (rectal Expulsion Device), allowing NeurAxis to commercially market the device for testing and evaluation of patients with chronic constipation due to pelvic floor dyssynergia and who are unlikely to improve with increased laxative use. NeurAxis will begin the process of commercially marketing RED and expects a soft launch in the first quarter of 2025 with a full launch expected in the second quarter of 2025. Management believes that providers will be able to bring this clinically beneficial technology to their practice immediately, given its clinical need and total addressable market of roughly $1.5 billion. There is currently a Category I CPT code assigned to the procedure and the procedure is covered by Medicare and most commercial insurance companies. RED can also be used as a qualitative test for rectal hypersensitivity. It will help identify patients who have an exaggerated urge to defecate, which also changes the treatment algorithm for patients with constipation.공시 • Nov 28Neuraxis, Inc. Appoints Dr. Aharon to the Board, Effective January 1, 2025NeurAxis, Inc. appointed Dr. Aharon to the Board, effective January 1, 2025. Dr. Aharon has not yet been appointed to any of the Board’s committees. Dr. Aharon’s compensation for serving as a director has not yet been determined. There are no family relationships between any of Dr. Aharon and any director or executive officer of the Company.New Risk • Nov 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 72% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$5.3m). Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$2.5m revenue). Market cap is less than US$100m (US$29.5m market cap).Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.26 loss per share (vs US$1.35 loss in 3Q 2023)Third quarter 2024 results: US$0.26 loss per share (improved from US$1.35 loss in 3Q 2023). Revenue: US$666.6k (up 40% from 3Q 2023). Net loss: US$1.76m (loss narrowed 64% from 3Q 2023).공시 • Nov 05+ 1 more updateNeurAxis, Inc. to Report Q3, 2024 Results on Nov 12, 2024NeurAxis, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024Reported Earnings • Aug 15Second quarter 2024 earnings released: US$0.42 loss per share (vs US$1.21 loss in 2Q 2023)Second quarter 2024 results: US$0.42 loss per share. Revenue: US$611.5k (down 5.3% from 2Q 2023). Net loss: US$2.92m (loss widened 20% from 2Q 2023).공시 • Aug 05NeurAxis, Inc. to Report Q2, 2024 Results on Aug 09, 2024NeurAxis, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 09, 2024공시 • Jun 24NeurAxis, Inc., Annual General Meeting, Aug 15, 2024NeurAxis, Inc., Annual General Meeting, Aug 15, 2024. Location: 11611 n. meridian st, suite 330, indiana 46032., carmel, United States공시 • May 24Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025NeurAxis, Inc. provided earnings guidance for late 2024 and 2025 . Given the company's recent success with new payor coverage, the company expects revenue to increase in late 2024 and into 2025.공시 • May 17+ 1 more updateNeurAxis, Inc. to Report Q1, 2024 Results on May 22, 2024NeurAxis, Inc. announced that they will report Q1, 2024 results Pre-Market on May 22, 2024공시 • Apr 17NeurAxis, Inc. Terminates Dan Clarence as Chief Operating OfficerOn April 10, 2024, the employment of Dan Clarence, Chief Operating Officer of NeurAxis, Inc., terminated effective immediately.공시 • Apr 10NeurAxis, Inc. Provides Revenue Guidance in Late 2024 and into 2025NeurAxis, Inc. provided revenue guidance for late 2024 and 2025. Given the company's recent success with new payor coverage, the company expects the company's revenue to increase in late 2024 and into 2025.공시 • Apr 02+ 1 more updateNeurAxis, Inc. to Report Q4, 2023 Results on Apr 09, 2024NeurAxis, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Apr 09, 2024공시 • Mar 27NeurAxis, Inc. Announces IB-Stim Results from A Large, Pediatric, Multi-Center RegistryNeurAxis, Inc. announced the results of a multicenter registry study on IB-Stim for pediatric disorders of gut-brain interaction (DGBI). IB-Stim is NeurAxis’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology therapy. The large and comprehensive study concluded efficacy of IB-Stim for gastrointestinal symptoms and functionality for pediatric disorders of gut-brain interaction (DGBI). Seven large, tertiary care centers in the US enrolled patients undergoing treatment with IB-Stim. Overall, 292 patients met Rome IV Diagnostic criteria for any pain associated disorder of the gut-brain interactions. In this cohort, 92% had failed medications therapy and 61% of patients had failed 4 or more medication when they entered the study. Patients were asked to fill out several validated pediatric measures, including the abdominal pain index (API), a validated questionnaire that assesses frequency, duration, and intensity of abdominal pain episodes. Data was collected weekly for the first 3 weeks and at 3, 6, 9 and 12 months. Compared to baseline scores, there were significant improvements in the API after 4 weeks of IB-Stim treatment at every time point, including 6 month (p<0.001) and 12 months (p<0.001).공시 • Mar 13Neuraxis, Inc. Appoints Kristin Ferge to the BoardOn March 7, 2024, the Board of Directors of NeurAxis, Inc. appointed Kristin Ferge to the Board to serve until the Company’s next annual meeting of shareholders. The Board has determined that Ms. Ferge is an independent director and meets the applicable director independence requirements of the NYSE American and rules promulgated by the Securities and Exchange Commission. The Board also appointed Ms. Ferge to Board’s Audit Committee as the Chairman of the Audit Committee. Kristin A. Ferge, 50, has been President and Chief Financial Officer of Capri Communities and Bridges Home Healthcare, a Wisconsin-based privately held senior living corporation, since 2016. Prior to joining Capri, Ms. Ferge was an executive for 18 years with Brookdale Senior Living Inc. or one of its predecessors. Ms. Ferge ended her tenure at Brookdale, a publicly traded senior living company, as Executive Vice President, Treasurer, and Chief Accounting Officer. Prior to Brookdale, Ms. Ferge was an auditor with KPMG. Ms. Ferge is a certified public accountant.Board Change • Feb 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Beth Keyser was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Nov 16NeurAxis, Inc. announced delayed 10-Q filingOn 11/14/2023, NeurAxis, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.81m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.4m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-US$10.0m). Market cap is less than US$10m (US$9.81m market cap). Minor Risk Revenue is less than US$5m (US$2.7m revenue).공시 • Sep 27NeurAxis, Inc. Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain DisordersNeurAxis, Inc. announced the results of a retrospective comparative study of adolescent patients with functional abdominal pain disorders (FAPD) treated with IB-Stim™ therapy or standard of care medications, amitriptyline (tricyclic antidepressant) or cyproheptadine (antihistamine). Led by the Cincinnati Children’s Hospital Medical Center, the comparative study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD. The publication, Percutaneous electrical nerve field stimulation compared to standard medical therapy in adolescents with functional abdominal pain disorders, featured in the September 19th 2023 Frontiers in Pain Research, reviewed records of 101 adolescents treated with 4 weeks of IB-Stim™, amitriptyline or cyproheptadine. In the study, 59% of patients in the IB-Stim group had failed prior standard medical therapy. Evaluated outcome measures included validated pediatric questionnaires using Abdominal Pain Index (API), Nausea Severity Scale (NSS) and Functional Disability Inventory (FDI) at baseline and at 3-month follow up. The comparative analysis noted that: at follow up, IB-Stim™ therapy showed improvements in abdominal pain (p=0.001) and functional disability (p=0.048) compared to baseline, while amitriptyline showed improvements in abdominal pain (p=0.034); in a comparison of outcomes between groups, IB-Stim™ was more effective than cyproheptadine in improving abdominal pain (p=0.04) and did not differ from amitriptyline (p=0.64). Nausea scores did not differ between groups (p>0.05); and disability scores between groups were only more effective for amitriptyline vs. cyproheptadine (p=0.03). Disability scores did not differ from amitriptyline compared with IB-Stim™ (p=0.21).Reported Earnings • Sep 22Second quarter 2023 earnings releasedSecond quarter 2023 results: US$1.12 loss per share. Net loss: US$2.24m (flat on 2Q 2022).공시 • Sep 13NeurAxis, Inc. Announces Publication of Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBSNeurAxis, Inc. announced the publication of Prospective study of the effect of auricular percutaneous electrical nerve field stimulation on quality of life in children with pain related disorders of gut-brain interaction, a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim™ in children with post-concussion symptoms, featured in the September 2023 Frontiers in Pain Research. The publication, led by investigators from Children’s Hospital of Orange County, investigated changes in gastrointestinal symptoms and quality of life in 31 adolescent patients aged 11 – 18 years with functional abdominal pain disorders (FAPDs) before and after treatment with IB-Stim. The patients were treated for 4 weeks and data were collected prospectively from both the patient and the parents using validated questionnaires. Following IB-Stim™ treatment, the study noted that: patients reported significant reductions in abdominal pain, nausea, disability, and anxiety from baseline to week 4 (p < 0.05); parent assessments reported significant improvement in the child’s quality of life based on physical function, psychosocial function, and generic core scale scores (p < 0.05); and parents also reported reduced abdominal pain, functional disability, and somatization in their child. The global health scores also significantly improved based on both patient and parent reports (p < 0.05).공시 • Sep 01Neuraxis, Inc. Highlights Pediatric Post-Concussion Clinical StudyNeurAxis, Inc. highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS(TM)) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo- controlled trial to evaluate the efficacy of IB-Stim(TM) in children with post-concussion symptoms. According to literature, the majority of concussions occur in children, mainly due to sports and unstructured play with or without helmets. While symptoms generally resolve in a few weeks, others persist, including ongoing headaches, nausea, and dizziness, as well as mood and behavioral disorders. Medications are primarily used for off-label in the treatment, despite the lack of evidence to support efficacy or safety. Currently enrolling up to 100 patients, the clinical trial's primary endpoint is improvements in validated measures, including the Immediate Post-Concussion Assessment, Post-Concussion Symptom Scale, and Balance Error Scoring Symptom compared to placebo. The trial is being conducted at Children's Hospital of Orange County, CA.Board Change • Aug 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Founder, Director of Design & Engineering and Director Gary Peterson was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Aug 10NeurAxis, Inc. has completed an IPO in the amount of $6.592002 million.NeurAxis, Inc. has completed an IPO in the amount of $6.592002 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,098,667 Price\Range: $6 Discount Per Security: $0.42 Transaction Features: Sponsor Backed Offering이익 및 매출 성장 예측NYSEAM:NRXS - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202833555112/31/202721-1N/AN/A112/31/202610-10-4-423/31/20264-8-6-6N/A12/31/20254-9-7-6N/A9/30/20253-8-6-6N/A6/30/20253-8-6-6N/A3/31/20253-9-6-6N/A12/31/20243-8-6-6N/A9/30/20242-8-7-7N/A6/30/20242-15-8-8N/A3/31/20242-15-7-7N/A12/31/20232-15-7-7N/A9/30/20233-13-4-4N/A6/30/20233-7-2-2N/A3/31/20233-7-3-3N/A12/31/20223-6-2-2N/A9/30/20223-6-2-2N/A12/31/20213-4-2-2N/A12/31/20202-4-4-4N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NRXS 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: NRXS (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: NRXS 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: NRXS 의 수익(연간 61.2%)이 US 시장(연간 12.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: NRXS 의 수익(연간 61.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NRXS의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/11 11:55종가2026/06/11 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스NeurAxis, Inc.는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Karen SterlingKingswood CapitalCasey RyanWestPark Capital, Inc.
Major Estimate Revision • May 19Consensus EPS estimates fall by 60%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$0.55 to -US$0.88 per share. Revenue forecast of US$10.2m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$11.00 unchanged from last update. Share price fell 9.1% to US$7.41 over the past week.
Major Estimate Revision • Mar 26Consensus revenue estimates increase by 12%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$8.50m to US$9.55m. EPS estimate unchanged at -US$0.54. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target up from US$7.00 to US$11.00. Share price fell 3.2% to US$6.93 over the past week.
Breakeven Date Change • Mar 19Forecast to breakeven in 2028The analyst covering NeurAxis expects the company to break even for the first time. New forecast suggests losses will reduce by 7.5% per year to 2027. The company is expected to make a profit of US$5.10m in 2028. Average annual earnings growth of 96% is required to achieve expected profit on schedule.
Price Target Changed • Nov 14Price target decreased by 20% to US$5.00Down from US$6.25, the current price target is an average from 2 analysts. New target price is 113% above last closing price of US$2.35. Stock is down 28% over the past year. The company is forecast to post a net loss per share of US$0.91 next year compared to a net loss per share of US$1.22 last year.
공시 • May 24Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025NeurAxis, Inc. provided earnings guidance for late 2024 and 2025 . Given the company's recent success with new payor coverage, the company expects revenue to increase in late 2024 and into 2025.
공시 • Apr 10NeurAxis, Inc. Provides Revenue Guidance in Late 2024 and into 2025NeurAxis, Inc. provided revenue guidance for late 2024 and 2025. Given the company's recent success with new payor coverage, the company expects the company's revenue to increase in late 2024 and into 2025.
Major Estimate Revision • May 19Consensus EPS estimates fall by 60%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$0.55 to -US$0.88 per share. Revenue forecast of US$10.2m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$11.00 unchanged from last update. Share price fell 9.1% to US$7.41 over the past week.
Reported Earnings • May 13First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$0.18 loss per share (improved from US$0.33 loss in 1Q 2025). Revenue: US$1.61m (up 80% from 1Q 2025). Net loss: US$1.95m (loss narrowed 22% from 1Q 2025). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 5.3%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.
공시 • May 05NeurAxis, Inc. to Report Q1, 2026 Results on May 12, 2026NeurAxis, Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026
공시 • Apr 29NeurAxis, Inc., Annual General Meeting, Jun 10, 2026NeurAxis, Inc., Annual General Meeting, Jun 10, 2026. Location: 11611 n., meridian st, suite 330, carmel, in 46032, United States
Major Estimate Revision • Mar 26Consensus revenue estimates increase by 12%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$8.50m to US$9.55m. EPS estimate unchanged at -US$0.54. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target up from US$7.00 to US$11.00. Share price fell 3.2% to US$6.93 over the past week.
Breakeven Date Change • Mar 19Forecast to breakeven in 2028The analyst covering NeurAxis expects the company to break even for the first time. New forecast suggests losses will reduce by 7.5% per year to 2027. The company is expected to make a profit of US$5.10m in 2028. Average annual earnings growth of 96% is required to achieve expected profit on schedule.
공시 • Mar 12NeurAxis, Inc. to Report Q4, 2025 Results on Mar 19, 2026NeurAxis, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 19, 2026
공시 • Jan 08NeurAxis, Inc. Achieves Major Milestone with AMA Category I CPT®? Code Now in Effect, Establishing A Permanent Reimbursement PathwayNeurAxis, Inc. announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now in effect, completing a successful commercial milestone for the Company. The assignment of the Category I CPT code is one of the most significant breakthroughs in efforts towards widespread adoption of IB-Stim®?. This establishes a permanent, nationally recognized coding and billing pathway for NeurAxis' PENFS therapy, reflecting broad clinical acceptance and meeting the American Medical Association's (AMA) criteria for widespread utilization, clinical efficacy, and established standards of care. Category I CPT codes are routinely used by Medicare, Medicaid, and commercial insurers as a basis for coverage and payment determinations. NeurAxis believes the code's implementation will expand patient access, reinforce the durability of its reimbursement model, and enhance the predictability of its commercial trajectory.
New Risk • Nov 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.3m free cash flow). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$3.5m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$3.4m revenue). Market cap is less than US$100m (US$24.9m market cap).
Price Target Changed • Nov 14Price target decreased by 20% to US$5.00Down from US$6.25, the current price target is an average from 2 analysts. New target price is 113% above last closing price of US$2.35. Stock is down 28% over the past year. The company is forecast to post a net loss per share of US$0.91 next year compared to a net loss per share of US$1.22 last year.
공시 • Nov 13NeurAxis, Inc. Announces New Medical Policy Coverage for Percutaneous Electrical Nerve Field Stimulation, Representing Approximately 566,000 Total Covered Lives, in MichiganNeurAxis, Inc. announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric beneficiaries in Michigan now have access to PENFS under medical policy. This expansion increases NeurAxis' total national coverage to roughly 55 million total lives, with additional payer decisions from major insurers expected in the coming months. NeurAxis' proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (nausea symptoms) in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in theear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns--underscoring IB-Stim's unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.
Reported Earnings • Nov 12Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.23 loss per share. Revenue: US$811.4k (up 22% from 3Q 2024). Net loss: US$2.32m (loss widened 29% from 3Q 2024). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 72% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.
공시 • Nov 04NeurAxis, Inc. to Report Q3, 2025 Results on Nov 11, 2025NeurAxis, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 11, 2025
공시 • Oct 24NeurAxis Receives First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia with Associated Nausea Symptoms in the Adult Patient PopulationNeurAxis, Inc. announced that it has received FDA 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (PENFS) technology for the treatment of functional abdominal pain (FAP) associated with functional dyspepsia (FD), and FD related nausea symptoms, in patients aged 8 years and older. The FDA reviewed the clinical literature supporting the use of NeurAxis' PENFS technology, including randomized controlled trials and real-world evidence demonstrating the device's safety and effectiveness in pediatric patients and individuals up to 21 years of age. Based on this comprehensive review, the FDA extrapolated the data to adults, supporting the use of PENFS in patients aged 8 years and years. This expanded indication marks a historic milestone, the first FDA clearance or approval for a treatment specifically addressing functional dyspepsia in adults. NeurAxis' PenFS technology is a non-surgical device that sends gentle electrical impulses into cranial nerve batteries in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction (DGBIs) and no approved drug therapies for adults for pain with functional dyspepsia. Pharmacologic treatments that use drugs off-label can often have serious side effects, and most lack scientific evidence of efficacy.
공시 • Aug 30NeurAxis, Inc. has filed a Follow-on Equity Offering in the amount of $3.3 million.NeurAxis, Inc. has filed a Follow-on Equity Offering in the amount of $3.3 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Aug 13Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: US$0.22 loss per share (improved from US$0.42 loss in 2Q 2024). Revenue: US$894.1k (up 46% from 2Q 2024). Net loss: US$1.90m (loss narrowed 35% from 2Q 2024). Revenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
공시 • Aug 05NeurAxis, Inc. to Report Q2, 2025 Results on Aug 12, 2025NeurAxis, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 12, 2025
공시 • Jun 10Neuraxis, Inc. Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (Fap) in IbsNeurAxis, Inc. announced that its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been officially incorporated into newly released clinical practice guidelines issued by the leading pediatric academic society for the treatment of Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS). This inclusion represents a major catalyst for NeurAxis, unlocking the potential for large-scale insurance coverage for its product, IB-Stim, and setting the stage for accelerated growth through evidence-based recommendations. This rigorous, evidence-based approach that incorporates PENFS as an important treatment option for children elevates NeurAxis's profile within the healthcare industry and supports wider market adoption of IB-Stim. Abdominal pain in IBS affects millions globally, creating a multi-billion-dollar market opportunity with limited effective treatment options. IB-Stim is the only pediatric treatment option that the FDA has cleared for FAP in IBS and abdominal pain in functional dyspepsia (to include nausea symptoms) for patients 8-21 years old. IB-Stim delivers gentle electrical impulses to cranial nerve bundles in the ear, offering a safe, non-invasive alternative to drug therapies often used off-label and many of which are not suggested in the practice guidelines from NASPGHAN /ESPGHAN.
New Risk • May 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (US$26.5m market cap).
공시 • May 23NeurAxis, Inc. has completed a Follow-on Equity Offering in the amount of $4.999998 million.NeurAxis, Inc. has completed a Follow-on Equity Offering in the amount of $4.999998 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,538,461 Price\Range: $3.25 Discount Per Security: $0.2275 Transaction Features: Registered Direct Offering
공시 • May 21NeurAxis, Inc. has filed a Follow-on Equity Offering in the amount of $4.999998 million.NeurAxis, Inc. has filed a Follow-on Equity Offering in the amount of $4.999998 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,538,461 Price\Range: $3.25 Discount Per Security: $0.2275 Transaction Features: Registered Direct Offering
Reported Earnings • May 13First quarter 2025 earnings released: US$0.33 loss per share (vs US$0.32 loss in 1Q 2024)First quarter 2025 results: US$0.33 loss per share (further deteriorated from US$0.32 loss in 1Q 2024). Revenue: US$895.7k (up 39% from 1Q 2024). Net loss: US$2.49m (loss widened 18% from 1Q 2024). Revenue is forecast to grow 59% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
공시 • May 05NeurAxis, Inc. to Report Q1, 2025 Results on May 12, 2025NeurAxis, Inc. announced that they will report Q1, 2025 results Pre-Market on May 12, 2025
New Risk • Apr 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.1m free cash flow). Earnings have declined by 28% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$2.7m revenue). Market cap is less than US$100m (US$14.1m market cap).
공시 • Apr 07NeurAxis, Inc., Annual General Meeting, May 29, 2025NeurAxis, Inc., Annual General Meeting, May 29, 2025. Location: at 11611 n., meridian st, suite 330, in 46032., carmel United States
Reported Earnings • Mar 21Full year 2024 earnings released: US$1.22 loss per share (vs US$4.50 loss in FY 2023)Full year 2024 results: US$1.22 loss per share (improved from US$4.50 loss in FY 2023). Revenue: US$2.69m (up 9.2% from FY 2023). Net loss: US$8.45m (loss narrowed 42% from FY 2023).
공시 • Mar 12NeurAxis, Inc. to Report Q4, 2024 Results on Mar 20, 2025NeurAxis, Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 20, 2025
공시 • Jan 22NeurAxis, Inc. Announces New Medical Policy Coverage with a Prominent Insurer for over Five Million Lives Across Multiple StatesNeurAxis, Inc. announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with a prominent insurer, with approximately 5.1 million members across 13 states. NeurAxis' PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction. Off label pharmacologic treatments can often have serious side effects, and most lack scientific evidence of efficacy.
공시 • Dec 11NeurAxis Inc. Announces FDA 510(k) Clearance of Red for Testing and Evaluation of Patients with Chronic ConstipationNeurAxis, Inc. announced the US Food and Drug Administration (FDA) granted a 510(k) clearance for RED (rectal Expulsion Device), allowing NeurAxis to commercially market the device for testing and evaluation of patients with chronic constipation due to pelvic floor dyssynergia and who are unlikely to improve with increased laxative use. NeurAxis will begin the process of commercially marketing RED and expects a soft launch in the first quarter of 2025 with a full launch expected in the second quarter of 2025. Management believes that providers will be able to bring this clinically beneficial technology to their practice immediately, given its clinical need and total addressable market of roughly $1.5 billion. There is currently a Category I CPT code assigned to the procedure and the procedure is covered by Medicare and most commercial insurance companies. RED can also be used as a qualitative test for rectal hypersensitivity. It will help identify patients who have an exaggerated urge to defecate, which also changes the treatment algorithm for patients with constipation.
공시 • Nov 28Neuraxis, Inc. Appoints Dr. Aharon to the Board, Effective January 1, 2025NeurAxis, Inc. appointed Dr. Aharon to the Board, effective January 1, 2025. Dr. Aharon has not yet been appointed to any of the Board’s committees. Dr. Aharon’s compensation for serving as a director has not yet been determined. There are no family relationships between any of Dr. Aharon and any director or executive officer of the Company.
New Risk • Nov 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 72% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$5.3m). Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$2.5m revenue). Market cap is less than US$100m (US$29.5m market cap).
Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.26 loss per share (vs US$1.35 loss in 3Q 2023)Third quarter 2024 results: US$0.26 loss per share (improved from US$1.35 loss in 3Q 2023). Revenue: US$666.6k (up 40% from 3Q 2023). Net loss: US$1.76m (loss narrowed 64% from 3Q 2023).
공시 • Nov 05+ 1 more updateNeurAxis, Inc. to Report Q3, 2024 Results on Nov 12, 2024NeurAxis, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024
Reported Earnings • Aug 15Second quarter 2024 earnings released: US$0.42 loss per share (vs US$1.21 loss in 2Q 2023)Second quarter 2024 results: US$0.42 loss per share. Revenue: US$611.5k (down 5.3% from 2Q 2023). Net loss: US$2.92m (loss widened 20% from 2Q 2023).
공시 • Aug 05NeurAxis, Inc. to Report Q2, 2024 Results on Aug 09, 2024NeurAxis, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 09, 2024
공시 • Jun 24NeurAxis, Inc., Annual General Meeting, Aug 15, 2024NeurAxis, Inc., Annual General Meeting, Aug 15, 2024. Location: 11611 n. meridian st, suite 330, indiana 46032., carmel, United States
공시 • May 24Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025NeurAxis, Inc. provided earnings guidance for late 2024 and 2025 . Given the company's recent success with new payor coverage, the company expects revenue to increase in late 2024 and into 2025.
공시 • May 17+ 1 more updateNeurAxis, Inc. to Report Q1, 2024 Results on May 22, 2024NeurAxis, Inc. announced that they will report Q1, 2024 results Pre-Market on May 22, 2024
공시 • Apr 17NeurAxis, Inc. Terminates Dan Clarence as Chief Operating OfficerOn April 10, 2024, the employment of Dan Clarence, Chief Operating Officer of NeurAxis, Inc., terminated effective immediately.
공시 • Apr 10NeurAxis, Inc. Provides Revenue Guidance in Late 2024 and into 2025NeurAxis, Inc. provided revenue guidance for late 2024 and 2025. Given the company's recent success with new payor coverage, the company expects the company's revenue to increase in late 2024 and into 2025.
공시 • Apr 02+ 1 more updateNeurAxis, Inc. to Report Q4, 2023 Results on Apr 09, 2024NeurAxis, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Apr 09, 2024
공시 • Mar 27NeurAxis, Inc. Announces IB-Stim Results from A Large, Pediatric, Multi-Center RegistryNeurAxis, Inc. announced the results of a multicenter registry study on IB-Stim for pediatric disorders of gut-brain interaction (DGBI). IB-Stim is NeurAxis’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology therapy. The large and comprehensive study concluded efficacy of IB-Stim for gastrointestinal symptoms and functionality for pediatric disorders of gut-brain interaction (DGBI). Seven large, tertiary care centers in the US enrolled patients undergoing treatment with IB-Stim. Overall, 292 patients met Rome IV Diagnostic criteria for any pain associated disorder of the gut-brain interactions. In this cohort, 92% had failed medications therapy and 61% of patients had failed 4 or more medication when they entered the study. Patients were asked to fill out several validated pediatric measures, including the abdominal pain index (API), a validated questionnaire that assesses frequency, duration, and intensity of abdominal pain episodes. Data was collected weekly for the first 3 weeks and at 3, 6, 9 and 12 months. Compared to baseline scores, there were significant improvements in the API after 4 weeks of IB-Stim treatment at every time point, including 6 month (p<0.001) and 12 months (p<0.001).
공시 • Mar 13Neuraxis, Inc. Appoints Kristin Ferge to the BoardOn March 7, 2024, the Board of Directors of NeurAxis, Inc. appointed Kristin Ferge to the Board to serve until the Company’s next annual meeting of shareholders. The Board has determined that Ms. Ferge is an independent director and meets the applicable director independence requirements of the NYSE American and rules promulgated by the Securities and Exchange Commission. The Board also appointed Ms. Ferge to Board’s Audit Committee as the Chairman of the Audit Committee. Kristin A. Ferge, 50, has been President and Chief Financial Officer of Capri Communities and Bridges Home Healthcare, a Wisconsin-based privately held senior living corporation, since 2016. Prior to joining Capri, Ms. Ferge was an executive for 18 years with Brookdale Senior Living Inc. or one of its predecessors. Ms. Ferge ended her tenure at Brookdale, a publicly traded senior living company, as Executive Vice President, Treasurer, and Chief Accounting Officer. Prior to Brookdale, Ms. Ferge was an auditor with KPMG. Ms. Ferge is a certified public accountant.
Board Change • Feb 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Beth Keyser was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Nov 16NeurAxis, Inc. announced delayed 10-Q filingOn 11/14/2023, NeurAxis, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.81m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.4m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-US$10.0m). Market cap is less than US$10m (US$9.81m market cap). Minor Risk Revenue is less than US$5m (US$2.7m revenue).
공시 • Sep 27NeurAxis, Inc. Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain DisordersNeurAxis, Inc. announced the results of a retrospective comparative study of adolescent patients with functional abdominal pain disorders (FAPD) treated with IB-Stim™ therapy or standard of care medications, amitriptyline (tricyclic antidepressant) or cyproheptadine (antihistamine). Led by the Cincinnati Children’s Hospital Medical Center, the comparative study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD. The publication, Percutaneous electrical nerve field stimulation compared to standard medical therapy in adolescents with functional abdominal pain disorders, featured in the September 19th 2023 Frontiers in Pain Research, reviewed records of 101 adolescents treated with 4 weeks of IB-Stim™, amitriptyline or cyproheptadine. In the study, 59% of patients in the IB-Stim group had failed prior standard medical therapy. Evaluated outcome measures included validated pediatric questionnaires using Abdominal Pain Index (API), Nausea Severity Scale (NSS) and Functional Disability Inventory (FDI) at baseline and at 3-month follow up. The comparative analysis noted that: at follow up, IB-Stim™ therapy showed improvements in abdominal pain (p=0.001) and functional disability (p=0.048) compared to baseline, while amitriptyline showed improvements in abdominal pain (p=0.034); in a comparison of outcomes between groups, IB-Stim™ was more effective than cyproheptadine in improving abdominal pain (p=0.04) and did not differ from amitriptyline (p=0.64). Nausea scores did not differ between groups (p>0.05); and disability scores between groups were only more effective for amitriptyline vs. cyproheptadine (p=0.03). Disability scores did not differ from amitriptyline compared with IB-Stim™ (p=0.21).
Reported Earnings • Sep 22Second quarter 2023 earnings releasedSecond quarter 2023 results: US$1.12 loss per share. Net loss: US$2.24m (flat on 2Q 2022).
공시 • Sep 13NeurAxis, Inc. Announces Publication of Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBSNeurAxis, Inc. announced the publication of Prospective study of the effect of auricular percutaneous electrical nerve field stimulation on quality of life in children with pain related disorders of gut-brain interaction, a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim™ in children with post-concussion symptoms, featured in the September 2023 Frontiers in Pain Research. The publication, led by investigators from Children’s Hospital of Orange County, investigated changes in gastrointestinal symptoms and quality of life in 31 adolescent patients aged 11 – 18 years with functional abdominal pain disorders (FAPDs) before and after treatment with IB-Stim. The patients were treated for 4 weeks and data were collected prospectively from both the patient and the parents using validated questionnaires. Following IB-Stim™ treatment, the study noted that: patients reported significant reductions in abdominal pain, nausea, disability, and anxiety from baseline to week 4 (p < 0.05); parent assessments reported significant improvement in the child’s quality of life based on physical function, psychosocial function, and generic core scale scores (p < 0.05); and parents also reported reduced abdominal pain, functional disability, and somatization in their child. The global health scores also significantly improved based on both patient and parent reports (p < 0.05).
공시 • Sep 01Neuraxis, Inc. Highlights Pediatric Post-Concussion Clinical StudyNeurAxis, Inc. highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS(TM)) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo- controlled trial to evaluate the efficacy of IB-Stim(TM) in children with post-concussion symptoms. According to literature, the majority of concussions occur in children, mainly due to sports and unstructured play with or without helmets. While symptoms generally resolve in a few weeks, others persist, including ongoing headaches, nausea, and dizziness, as well as mood and behavioral disorders. Medications are primarily used for off-label in the treatment, despite the lack of evidence to support efficacy or safety. Currently enrolling up to 100 patients, the clinical trial's primary endpoint is improvements in validated measures, including the Immediate Post-Concussion Assessment, Post-Concussion Symptom Scale, and Balance Error Scoring Symptom compared to placebo. The trial is being conducted at Children's Hospital of Orange County, CA.
Board Change • Aug 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Founder, Director of Design & Engineering and Director Gary Peterson was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Aug 10NeurAxis, Inc. has completed an IPO in the amount of $6.592002 million.NeurAxis, Inc. has completed an IPO in the amount of $6.592002 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,098,667 Price\Range: $6 Discount Per Security: $0.42 Transaction Features: Sponsor Backed Offering